Blida

Researchers are conducting a prospective, multicenter, observational study called SAFRO 2202 ALG-Lung Cancer Registry to gather detailed information about lung cancer patients in Algeria. The study focuses on understanding the epidemiological, clinical, pathological, molecular, and treatment characteristics of adults diagnosed with lung cancer, including non-small cell lung cancer, small cell lung cancer, and carcinoid tumors. This research aims to fill gaps in real-world data on lung cancer management and outcomes across Algeria's public healthcare system. The study involves collecting data during routine clinical care at 21 public and university hospitals specialized in oncology and pulmonology. Eligible adults, diagnosed at inclusion or within the prior 12 months, have their demographic information, tumor histology, molecular profiles, staging, and treatment details recorded in a secure electronic case report form. Treatments include surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy, but no additional study-specific procedures or visits are required. Participants' medical history, risk factors, treatment responses, and adverse events are monitored through standard care over at least 12 months. The study measures key outcomes such as tumor characteristics at diagnosis, treatment modalities, progression-free survival, treatment discontinuation time, and overall survival. This large-scale registry, enrolling around 1,500 patients yearly over 30 months, aims to support national health planning and improve lung cancer care in Algeria.

Researchers are evaluating how effective and well-tolerated the subcutaneous form of trastuzumab-pertuzumab (Phesgo) is when given before surgery to Algerian women with early-stage, HER2-positive breast cancer. The study focuses on women diagnosed with non-metastatic HER2-positive breast cancer and aims to measure the rate of complete destruction of invasive cancer in the breast and nearby lymph nodes, known as pathological complete response (pCR). This real-world study also explores treatment side effects, quality of life, patient satisfaction, and factors that might predict response. Participants will receive Phesgo combined with standard chemotherapy over approximately 18 weeks before undergoing surgery. The treatment is given as a neoadjuvant therapy, meaning it is administered prior to surgery to shrink the tumor. This study takes place in three oncology centers in Algeria, including Blida, Aïn Defla, and Médéa, and involves around 70 adult women. During the study, participants will be monitored to assess cancer response at the time of surgery, about 18 to 24 weeks after starting treatment. Researchers will track the pathological complete response rate as the primary outcome. Other assessments include side effects, heart function, quality of life, and treatment satisfaction. The study aims to understand if Phesgo can simplify treatment delivery, reduce hospital burden, and improve access to care in Algeria where healthcare resources are limited.

This research aims to evaluate the combination of hormone therapy (Letrozole or Anastrozole) and Palbociclib in women with newly diagnosed metastatic luminal hormone receptor-positive, HER2 negative advanced breast cancer. This international, multicenter, open-label phase II study focuses on pre and postmenopausal patients to predict individual treatment responses using a novel Quantum Optics technology applied on liquid biopsies. The goal is to identify which patients are likely to benefit from this standard combination, addressing the current lack of predictive markers for treatment effectiveness. Participants will receive a combination of Palbociclib taken orally at 125 mg daily for three weeks followed by one week off, with dose adjustments based on safety, together with daily oral aromatase inhibitors (Letrozole 2.5 mg or Anastrozole 1 mg). For pre/peri-menopausal patients, ovarian function suppression may also be included. Treatment continues until disease progression, with response evaluations every three months using clinical and radiological assessments. Liquid biopsies for plasma molecular fingerprinting using Quantum Optics technology will be collected at enrollment, monthly for the first three months, and then every three months to monitor molecular changes. Participants will undergo regular clinical and radiological assessments every three months to evaluate disease status according to Revised RECIST guidelines. Blood samples will be taken for molecular analysis to predict treatment efficacy and monitor progression. Researchers will measure the rate of objective clinical response and assess the sensitivity and specificity of the Quantum Optics technology in predicting treatment outcomes, with follow-up planned for up to two years. Safety and tolerability of the treatment combination will also be monitored throughout the study.

Researchers are describing the demographic, epidemiological, clinical, and outcome characteristics of patients diagnosed with prostate cancer in Algeria. The study also analyzes the diagnostic methods and treatment approaches used for managing these patients. This is a descriptive, cross-sectional clinical study including patients with histologically or biologically confirmed prostate cancer. The study plans to enroll 500 patients who are being followed in participating oncology centers. Data collection involves reviewing medical records and conducting structured patient interviews lasting approximately 30 minutes. A standardized electronic case report form is used to ensure data completeness and accuracy. Information gathered includes sociodemographic details, medical history, disease characteristics, diagnostic tests performed, and treatments implemented. Participants are evaluated at the initial visit with assessments including socio-demographic factors, personal and family cancer history, environmental and occupational exposures, smoking and alcohol use, initial symptoms, and diagnosis circumstances. The International Prostate Symptom Score (IPSS) and disease status are also recorded. All collected data is anonymized and used solely for research. The study focuses on baseline characteristics without interventional treatments or long-term follow-up described.